ADAPTIVE BIOTECHNOLOGIES CORPORATION Increase (Decrease) in Accounts Payable and Accrued Liabilities
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$6.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.01M, a 69.10% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$7.51M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.17M, a 72.68% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $5.90M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $665.00K, a 0.89% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $671.00K.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$5.41M, a 176.04% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $7.11M, a 80.48% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$6.50M 10-Q · filed 2026-08-04 | -$5.34M derived: sum of 3 quarters · filed 2026-08-04 | $559.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$7.51M 10-Q · filed 2026-05-05 | -$6.35M derived: sum of 2 quarters · filed 2026-05-05 | -$451.00K derived: sum of 3 quarters · filed 2026-05-05 | $2.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.06M derived: sum of 2 quarters · filed 2026-02-26 | $10.33M derived: sum of 3 quarters · filed 2026-08-04 | $665.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $9.16M derived: sum of 2 quarters · filed 2026-08-04 | -$500.00K 10-Q · filed 2025-11-05 | $3.76M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $3.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$6.40M 10-Q · filed 2026-08-04 | -$2.13M derived: sum of 3 quarters · filed 2026-08-04 | -$2.19M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$9.66M 10-Q · filed 2026-05-05 | -$5.40M derived: sum of 2 quarters · filed 2026-05-05 | -$5.46M derived: sum of 3 quarters · filed 2026-05-05 | -$5.05M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.21M derived: sum of 2 quarters · filed 2026-02-26 | $4.61M derived: sum of 3 quarters · filed 2026-02-26 | $671.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $348.00K derived: sum of 2 quarters · filed 2025-11-05 | -$3.59M 10-Q · filed 2025-11-05 | $1.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $407.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$3.53M 10-Q · filed 2025-08-05 | $1.80M derived: sum of 3 quarters · filed 2026-02-26 | -$1.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$3.94M 10-Q · filed 2025-05-01 | $1.40M derived: sum of 2 quarters · filed 2026-02-26 | -$1.41M derived: sum of 3 quarters · filed 2026-02-26 | $6.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $5.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.53M derived: sum of 2 quarters · filed 2026-02-26 | $10.47M derived: sum of 3 quarters · filed 2026-02-26 | -$5.41M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$2.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.13M derived: sum of 2 quarters · filed 2024-11-07 | -$10.75M 10-Q · filed 2024-11-07 | -$216.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $7.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$7.94M 10-Q · filed 2024-08-01 | $2.59M derived: sum of 3 quarters · filed 2025-03-03 | $8.13M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$15.88M 10-Q · filed 2024-05-07 | -$5.35M derived: sum of 2 quarters · filed 2025-03-03 | $189.00K derived: sum of 3 quarters · filed 2025-03-03 | -$1.22M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $10.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $16.07M derived: sum of 2 quarters · filed 2025-03-03 | $14.66M derived: sum of 3 quarters · filed 2025-03-03 | $7.11M 10-K · filed 2025-03-03 |
| 2022-09-30 | $5.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.13M derived: sum of 2 quarters · filed 2023-11-09 | -$3.42M 10-Q · filed 2023-11-09 | -$5.00M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$8.96M 10-Q · filed 2023-08-02 | -$10.53M derived: sum of 3 quarters · filed 2024-02-29 | -$2.54M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$7.54M 10-Q · filed 2023-05-03 | -$9.12M derived: sum of 2 quarters · filed 2024-02-29 | -$1.13M derived: sum of 3 quarters · filed 2024-02-29 | $3.65M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $6.42M derived: sum of 2 quarters · filed 2024-02-29 | $11.20M derived: sum of 3 quarters · filed 2024-02-29 | $3.94M 10-K · filed 2024-02-29 |
| 2021-09-30 | $7.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $12.78M derived: sum of 2 quarters · filed 2022-11-03 | $5.52M 10-Q · filed 2022-11-03 | $12.98M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $4.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$2.48M 10-Q · filed 2022-08-03 | $4.99M derived: sum of 3 quarters · filed 2023-02-14 | $6.91M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | -$7.26M 10-Q · filed 2022-05-04 | $208.00K derived: sum of 2 quarters · filed 2023-02-14 | $2.13M derived: sum of 3 quarters · filed 2023-02-14 | $4.84M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $7.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $9.39M derived: sum of 2 quarters · filed 2023-02-14 | $12.10M derived: sum of 3 quarters · filed 2023-02-14 | $7.50M 10-K · filed 2023-02-14 |
| 2020-09-30 | $1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $4.63M derived: sum of 2 quarters · filed 2021-11-03 | $30.00K 10-Q · filed 2021-11-03 | $3.05M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$1.89M 10-Q · filed 2021-08-04 | $1.13M derived: sum of 3 quarters · filed 2022-02-15 | $2.94M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$4.60M 10-Q · filed 2021-05-05 | -$1.58M derived: sum of 2 quarters · filed 2022-02-15 | $232.00K derived: sum of 3 quarters · filed 2022-02-15 | $1.92M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $4.83M derived: sum of 2 quarters · filed 2022-02-15 | $6.53M derived: sum of 3 quarters · filed 2022-02-15 | $6.15M 10-K · filed 2022-02-15 |
| 2019-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $3.51M derived: sum of 2 quarters · filed 2020-11-10 | $3.13M 10-Q · filed 2020-11-10 | $3.59M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.31M 10-Q · filed 2020-08-10 | $1.77M derived: sum of 3 quarters · filed 2021-02-24 | $4.51M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | -$377.00K 10-Q · filed 2020-05-12 | $79.00K derived: sum of 2 quarters · filed 2021-02-24 | $2.82M derived: sum of 3 quarters · filed 2021-02-24 | |
| 2018-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $3.20M derived: sum of 2 quarters · filed 2021-02-24 | $2.19M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $2.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $1.73M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | -$1.01M 10-Q · filed 2019-08-13 | |||
| 2017-12-31 | -$1.52M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |